Gestadienol acetate

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Gestadienol acetate
Gestadienol acetate.svg
Clinical data
Other namesCIBA-31458-Ba; CIBA-31458; Norhydroxy-δ6-progesterone acetate; 6-Dehydro-17α-acetoxy-19-norprogesterone; 17α-Acetoxy-19-norpregn-4,6-diene-3,20-dione
Routes of
administration
By mouth[1][2]
Drug classProgestogen; Progestogen ester
Identifiers
CAS Number
PubChem CID
ECHA InfoCard100.224.529 Edit this at Wikidata
Chemical and physical data
FormulaC22H28O4
Molar mass356.462 g/mol g·mol−1
3D model (JSmol)

Gestadienol acetate (developmental code name CIBA-31458-Ba or CIBA-31458) an orally active progestin which was described in the literature in 1967 and was never marketed.[3][1][2][4][5] It has no androgenic or estrogenic effects.[6] The effects of gestadienol acetate on the endometrium and its general pharmacology were studied in a clinical trial in women.[2][5] It has also been studied in a clinical trial for benign prostatic hyperplasia in men, but was ineffective.[6]

Chemistry[edit]

Gestadienol acetate, also known as norhydroxy-δ6-progesterone acetate, 6-dehydro-17α-hydroxy-19-norprogesterone 17α-acetate, or 17α-hydroxy-19-norpregn-4,6-diene-3,20-dione 17α-acetate, is a synthetic norpregnane steroid and a derivative of progesterone.[3] It is specifically a combined derivative of 17α-hydroxyprogesterone and 19-norprogesterone, or of gestronol (17α-hydroxy-19-norprogesterone), with an acetate ester at the C17α position and a double bond between the C6 and C7 positions.[3] Gestadienol acetate is the C17α acetate ester of gestadienol.[3] Analogues of gestadienol acetate include algestone acetophenide (dihydroxyprogesterone acetophenide), demegestone, gestonorone caproate (norhydroxyprogesterone caproate), hydroxyprogesterone acetate, hydroxyprogesterone caproate, nomegestrol acetate, norgestomet, and segesterone acetate (nestorone).[3]

References[edit]

  1. ^ a b Desaulles, P. A.; Krahenbuhl, C. (1967). "Biological Properties of a New Progesterone Analogue". European Journal of Endocrinology. 56 (1 Suppl): S143–S143. doi:10.1530/acta.0.056S143. ISSN 0804-4643.
  2. ^ a b c Gupta, A. (1967, January). Effect of the new progestogen, CIBA 31458 on the human endometrium. In Journal of Reproduction and Fertility (Vol. 14, No. 3, p. 530). 22 Newmarket Rd, Cambridge CB5 8DT, England: Journal of Reproduction and Fertility LTD. http://www.reproduction-online.org/content/14/3/523.full.pdf
  3. ^ a b c d e J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. p. 659. ISBN 978-1-4757-2085-3.
  4. ^ Petrow V (1970). "The contraceptive progestagens". Chem. Rev. 70 (6): 713–26. doi:10.1021/cr60268a004. PMID 4098492.
  5. ^ a b Heusler K, Kalvoda J (1996). "Between basic and applied research: Ciba's involvement in steroids in the 1950s and 1960s". Steroids. 61 (8): 492–503. doi:10.1016/0039-128x(96)00040-2. PMID 8870170.
  6. ^ a b Hald T, From A (1972). "Benign prostatic hypertrophy treated with a gestagen. A double-blind clinical trial with randomized allocation". Scand. J. Urol. Nephrol. 6: Suppl 15:157–6. PMID 4118753.